Antibodies specific to MUC18 (a.k.a. MCAM or CD146) and uses thereof for therapeutic and diagnostic purposes are provided. Also provided herein are chimeric antigen receptors (CARs) comprising an extracellular antigen-binding fragment that binds MUC18 and immune cells expressing such.

Provided herein are FRAME immunogenic peptides, binding proteins recognizing FRAME immunogenic peptides, and uses thereof.

The present invention relates to methods for producing immuno-stimulatory autologous dendritic cells. The present invention further relates to the use of such cells for treating patients suffering from hyper-proliferative disease such as cancer.

Disclosed herein are invariant natural killer T (iNKT) cells engineered using hematopoietic stem and progenitor cells (HSPCs) and methods of making and using thereof.

The present disclosure provides NK cells useful for therapy. A Natural Killer (NK)-cell includes nucleic acids for expressing an T-cell Receptor (TCR), CD3, CD3, CD3 and CD3 in its cell membrane, and a nucleic acid for expressing and secreting a bispecific protein, wherein the bispecific protein includes a first Fv for binding to a first target epitope and a second Fv for binding to a second target epitope, wherein the first Fv specifically binds, under physiological conditions, to an epitope located on the extracellular part of a CD3-chain, and wherein the second Fv specifically binds, under physiological conditions, to an epitope located on target cells.

Provided herein are multiplexed T cell receptor compositions, combination therapies, and uses thereof.

Disclosed are modified DAP12 and methods of their use for enhancing immune responses and for treating cancer.

The invention provides systems and methods for determining and predicting the effect of providing a population of tumor infiltrating lymphocytes (TILs) on a condition associated with an entity, for example the effect of providing a population of tumor infiltrating lymphocytes (TILs) on a subject having cancer. The systems and methods rely on acquiring a computer readable analytical signature from a sample of the entity, obtaining a trained model output value for the entity by inputting the computer readable analytical signature into a tier trained model panel, and classifying the entity based upon the trained model output value with a time-to-event class in an enumerated set of time-to-event classes, each of whom is associated with a different effect of providing a population of TILs to the entity.

The invention provides methods of treating cancer in a patient by administering a therapeutically effective population of TILs to the patient, which is at the same determined to be likely to benefit from the administration of TILs comparative to other cancer patients that have been administered TILs. Such methods of treatment include obtaining from the patient a tumor fragment, contacting the tumor fragment with one or more cell culture mediums, thereby performing one or more expansions of population of TILs existing in the tumor, and producing one or more subsequent populations of TILs. The invention also provides methods of treating cancer in a patient exhibiting an increased or decreased level of expression of various biological markers.

There are disclosed inter alia polypeptides and nucleic acids encoding said polypeptides which are useful in the treatment, prevention and diagnosis of cancer, particularly melanoma, especially cutaneous melanoma and uveal melanoma.

The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.